PAR
Par Drugs And Chemicals Limited (PAR) Stock Analysis
Par Drugs and Chemicals Limited manufactures active pharmaceutical ingredients and intermediates for domestic and export markets. It supplies APIs used in antibiotics and specialty therapies. The company operates API plants with regulatory compliance focus. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹117.10
-5.53% 1W | +21.60% 52W
Market Cap
144 CR
P/E Ratio
11
52W High
₹180
52W Low
₹78
Div. Yield
0%
Beta
0.4
50 DMA
₹119.6
200 DMA
₹98.8
Profit Margin
13.3%
Inst. Own.
0%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.93 | 25.89 | 24.00 | 22.82 | 22.61 | 34.66 | 21.38 | 22.33 | 26.05 | 28.66 | 29.34 | 19.61 | 31.28 |
| Expenses | 18.79 | 18.53 | 18.77 | 16.72 | 18.37 | 23.25 | 19.95 | 19.90 | 22.49 | 22.60 | 23.29 | 18.17 | 24.91 |
| Operating Profit | 4.14 | 7.36 | 5.23 | 6.10 | 4.24 | 11.41 | 1.43 | 2.43 | 3.56 | 6.06 | 6.05 | 1.44 | 6.37 |
| OPM % | 18.05% | 28.43% | 21.79% | 26.73% | 18.75% | 32.92% | 6.69% | 10.88% | 13.67% | 21.14% | 20.62% | 7.34% | 20.36% |
| Other Income | 0.01 | 0.05 | 0.23 | -0.05 | 0.07 | 1.02 | 0.27 | 0.79 | 1.84 | 0.48 | 1.33 | 0.36 | 0.94 |
| Interest | 0.02 | 0.03 | 0.02 | 0.05 | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 | 0.05 | 0.01 | 0.04 | 0.02 |
| Depreciation | 0.83 | 0.85 | 0.87 | 0.89 | 0.90 | 0.91 | 0.91 | 0.92 | 0.90 | 0.94 | 0.93 | 0.93 | 0.96 |
| Profit before tax | 3.30 | 6.53 | 4.57 | 5.11 | 3.39 | 11.49 | 0.78 | 2.28 | 4.48 | 5.55 | 6.44 | 0.83 | 6.33 |
| Tax % | 25.15% | 25.27% | 25.16% | 27.20% | 25.07% | 25.15% | 24.36% | 27.63% | 25.67% | 25.59% | 25.47% | -3.61% | 25.59% |
| Net Profit | 2.47 | 4.89 | 3.42 | 3.72 | 2.53 | 8.60 | 0.58 | 1.65 | 3.33 | 4.13 | 4.80 | 0.85 | 4.71 |
| EPS in Rs | 2.01 | 3.97 | 2.78 | 3.02 | 2.06 | 6.99 | 0.47 | 1.34 | 2.71 | 3.36 | 3.90 | 0.69 | 3.83 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 33 | 49 | 42 | 46 | 56 | 61 | 75 | 96 | 96 | 101 | 104 | 109 |
| Expenses | 26 | 26 | 40 | 34 | 38 | 46 | 45 | 59 | 78 | 73 | 81 | 87 | 89 |
| Operating Profit | 7 | 7 | 8 | 8 | 8 | 9 | 16 | 16 | 18 | 23 | 20 | 17 | 20 |
| OPM % | 22% | 22% | 17% | 19% | 18% | 17% | 26% | 22% | 19% | 24% | 19% | 17% | 18% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 4 | 3 |
| Interest | 4 | 4 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Profit before tax | 1 | 1 | 3 | 3 | 3 | 6 | 15 | 13 | 15 | 20 | 18 | 17 | 19 |
| Tax % | 27% | 58% | 42% | 42% | 24% | 21% | 21% | 27% | 25% | 26% | 26% | 24% | |
| Net Profit | 1 | 0 | 2 | 2 | 3 | 5 | 12 | 9 | 11 | 14 | 13 | 13 | 14 |
| EPS in Rs | 1.65 | 0.78 | 3.43 | 2.78 | 2.79 | 3.87 | 9.44 | 7.49 | 9.21 | 11.78 | 10.86 | 10.65 | 11.78 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | 32% | -0% | -0% | -0% | -0% | -0% | -0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 3.0% | 11.0% | 12.0% |
| Profit CAGR | -2.0% | 1.0% | 38.0% |
Shareholding Pattern
Promoters73.37%
Public26.63%
Promoters73.37%
Public26.63%
Promoters73.41%
Public26.59%
Promoters73.41%
Public26.59%
Promoters73.41%
DIIs0.09%
Public26.51%
Promoters74.21%
Public25.79%
Promoters74.21%
FIIs0.07%
DIIs0.05%
Public25.68%
Promoters73.37%
Public26.63%
Promoters73.41%
Public26.59%
Promoters73.41%
DIIs0.09%
Public26.51%
PAR
Holdings Analysis
Key strengths & risk signals
66
Overall
58
Fundamental
74
Technical
Risks (4)
OVERVALUED! PEG of 11.00 means expensive relative to growth rate.
RECOVERY MODE! Current price (117.1) above 200-day but below 50-day.
LOWER HALF! Trading at 38.3% of 52W range - weakness visible.
WEAK MOMENTUM! Limited price growth - -5.5% (1 week), -12.8% (1 month), 30.7% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (119.6) is above 200-day average (98.8) - positive signal.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 205,694 vs down days: 59,448. Ratio: 3.46x
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
Fundamental & Technical Analysis
66Overall
58Fundamental
74Technical
Fundamental Breakdown
Growth Quality
16/30
Revenue CAGR: 11.0% (GOOD, 11/15). Profit CAGR: 1.0% (SLOW, 5/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.3% profit margin - acceptable profitability.
PEG Valuation
0/10
OVERVALUED! PEG of 11.00 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 25.79% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (119.6) is above 200-day average (98.8) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (117.1) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
8/10
GOOD YEAR! Stock gained 21.6% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 205,694 vs down days: 59,448. Ratio: 3.46x
RSI
3/5
NEUTRAL! RSI at 41.6 - balanced momentum.
52W Range
2/5
LOWER HALF! Trading at 38.3% of 52W range - weakness visible.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -5.5% (1 week), -12.8% (1 month), 30.7% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAR | ₹117.10 | 11 | 13.3% | 11.0% | 1.0% | +21.6% | 66 | BREAKDOWN | +42.7% | +423.3% | +20.3% | +59.6% |
| BALPHARMA | ₹93.10 | 20.5 | 2.2% | 0.1% | 34.7% | +18.7% | 66 | CONSOLIDATING UP | +450.0% | -69.4% | +34.4% | +5.4% |
| BALAXI | ₹22.30 | 49.6 | 0.5% | -7.1% | -68.6% | -48.5% | 51 | APPROACHING SUPPORT | +333.3% | +116.7% | +14.1% | +14.1% |
| NATCAPSUQ | ₹160.00 | – | -8.1% | 3.6% | – | -32.4% | 46 | BREAKDOWN | +1.8% | +14.0% | +7.7% | -16.8% |
| KREBSBIO | ₹56.00 | – | -55.9% | -23.1% | – | -16.8% | 47 | BREAKDOWN | -52.8% | +8.7% | +27.3% | +2.9% |
| ALPA | ₹57.00 | 33.9 | 3.8% | 4.3% | 6.1% | -35.3% | 47 | APPROACHING SUPPORT | -91.5% | -28.6% | +25.1% | -23.9% |
| VAISHALI | ₹7.90 | – | 4.1% | 18.0% | -15.2% | -26.8% | 52 | BREAKDOWN | – | +278.0% | – | -15.0% |
| MEDICO | ₹22.80 | 13.7 | 5.8% | 13.8% | 21.9% | -55.7% | 55 | BREAKDOWN | +38.9% | -57.6% | +81.2% | +22.2% |
Data from TradeAlone · Updated daily
No news tagged for PAR yet.
